St Paul, MN, January 9, 2007 - MD Biosciences, a global biotechnology company focused in inflammations research, accounces the launch of its new and improved Collagen Type II (CII) ELISA for the study of collagen metabolism. CII is a triple stranded pro-molecule that is found predomiinantly, but not exclusively, in cartilage. It's promary role is to provide cartilage with tensile strength and elasticity. Autoimmunity to CII is thought to play a role in the pathogenesis of many autoimmune diseases such as rheumatoid arthritis.
This ELISA offers many improvements over other commercially available CII ELISAs such as increased sensitivity, reproducibility, and accuracy for the reliability of results. The ELISA is designed to quantify the amount of collagen type II produced by cells or present in tissue across a variety of species. The ELISA is also highly specific to CII offering no cross-reactivity to other types of collagen providing reliable results.
In addition to performance improvements, user-friendly improvements such as pre-coated microplates and ready-to-use reagents increase the usability and decrease the preparation time allowing researchers to obtain rapid results in less than 5 hours.
About MD Biosciences
MD Biosciences provides products and pre-clinical services to companies engaged in inflammation and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to provide flexible drug discovery solutions, enabling smarter results faster.